# MC-Gly-Gly-Phe-Gly-GABA-Exatecan

| | |
|---|---|
| **Cat. No.:** | HY-160649 |
| **CAS No.:** | 1599439-52-7 |
| **Molecular Formula:** | $C_{53}H_{58}FN_9O_{12}$ |
| **Molecular Weight:** | 1032.08 |
| **Target:** | Drug-Linker Conjugates for ADC; Topoisomerase |
| **Pathway:** | Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage |
| **Storage:** | -20°C, sealed storage, away from moisture and light<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (96.89 mM; Need ultrasonic)

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 0.9689 mL | 4.8446 mL | 9.6892 mL |
| | 5 mM | 0.1938 mL | 0.9689 mL | 1.9378 mL |
| | 10 mM | 0.0969 mL | 0.4845 mL | 0.9689 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with $IC_{50}$ of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo[1][2].

**$IC_{50}$ & Target**

Camptothecins

**In Vitro**

MC-Gly-Gly-Phe-Gly-GABA-Exatecan (0-10 μM) exhibits cytotoxicity in cells SR (CD30 positive), HL60 (CD33 positive), U251 (CD70 positive) and Calu-6 (B7-H3 positive) through functions with CD30, CD33, CD70 and B7-H3[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

| | |
|---|---|
| Cell Line: | SR, HL60, U251 and Calu-6 |
| Concentration: | 0-10 μM |
| Incubation Time: | 6 days |

| | |
|---|---|
| Result: | Reduced cell viability. |

**In Vivo**

MC-Gly-Gly-Phe-Gly-GABA-Exatecan (10 mg/kg, i.v. once a week for 2 weeks) exhibits antitumor efficacy in A375 xenograft mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | A375 xenograft mice[2] |
| Dosage: | 10 mg/kg |
| Administration: | i.v, once a week for 2 weeks |
| Result: | Inhibited tumor growth and induced tumor regression. |

## REFERENCES


[1]. Hettmann T, et al., Anti-her3 antibody-drug conjugate. Patent WO2015155998

[2]. Ogitani Y, et al., Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett. 2016 Oct 15;26(20):5069-5072.





Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA